MLYS Mineralys Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1933414 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-115.9%
TTM EPS YoY-47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-68.5%
ROA-60.2%
ROIC (approx.)-80.9%
Asset turnover—
Leverage & solvency
Liabilities / assets20.1%
Debt / equity0.00x
Current ratio11.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.41x
Accruals ratio-35.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $132.01M | $168.58M | $70.36M | $26.25M |
| SG&A expense | $38.59M | $23.82M | $14.30M | $5.23M |
| Operating income | -$170.60M | -$192.40M | -$84.66M | -$31.48M |
| Income tax | $0 | — | — | — |
| Net income | -$154.65M | -$177.81M | -$71.90M | -$29.80M |
| EBITDA | -$170.54M | -$192.36M | -$84.66M | — |
| EPS (basic) | -2.29 | -3.66 | -1.99 | -5.77 |
| EPS (diluted) | -2.29 | -3.66 | -1.99 | -5.77 |
| Weighted avg. shares (diluted) | 67.66M | 48.54M | 36.19M | 5.17M |
| Balance sheet | ||||
| Cash & equivalents | $172.92M | $114.09M | $49.30M | $87.70M |
| Current assets | $661.39M | $205.35M | $249.10M | $112.81M |
| PP&E, net | $38,000 | $53,000 | $0 | — |
| Total assets | $661.81M | $205.90M | $251.64M | $114.44M |
| Current liabilities | $15.11M | $14.65M | $10.48M | $8.07M |
| Total liabilities | $15.11M | $14.65M | $10.48M | $166.71M |
| Shareholders' equity | $646.69M | $191.26M | $241.15M | -$52.27M |
| Shares outstanding | 81.54M | 49.82M | 41.13M | 6.42M |
| Cash flow statement | ||||
| Operating cash flow | -$142.42M | -$166.31M | -$81.17M | -$29.22M |
| Capital expenditure | $15,000 | $96,000 | $0 | — |
| Free cash flow | -$142.43M | -$166.41M | -$81.17M | — |
| Investing cash flow | -$389.75M | $114.96M | -$160.47M | -$21.76M |
| Financing cash flow | $591.00M | $116.14M | $203.25M | $128.02M |
| Depreciation & amortization | $59,000 | $43,000 | $0 | — |
| Stock-based compensation | $19.32M | $11.34M | $5.06M | $455,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.